<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="211">
  <stage>Registered</stage>
  <submitdate>17/08/2005</submitdate>
  <approvaldate>25/08/2005</approvaldate>
  <actrnumber>ACTRN12605000207617</actrnumber>
  <trial_identification>
    <studytitle>Fish Oils (Omega 3) in ischaemic stroke</studytitle>
    <scientifictitle>A Randomised, Placebo-Controlled Intervention Trial of Omega-3 PUFA, (Fish Oils), in People with Ischaemic Stroke</scientifictitle>
    <utrn />
    <trialacronym>FOILS</trialacronym>
    <secondaryid>HRC</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ischaemic Cerebrovascular Disease</healthcondition>
    <healthcondition>Ischaemic Cerebrovascular Stroke</healthcondition>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants receive 3 gm of fish oil (containing omega-3 PUFAs) orally for the treatment group Participants are seen at 0 and 12 weeks for clinical assessments, anthropometry, venepuncture for haematological and biochemical analyses, assessment of compliance and the recording of adverse events.  In addition, a telephone follow-up visit will be performed at 6 and 11 weeks to ascertain safety data (SAEs) and compliance to study treatment.</interventions>
    <comparator>Placebo (palm and soy oil) for the control group for 12 weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the effectiveness of Omega-3 PUFAs in improving lipid profiles</outcome>
      <timepoint>At 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the treatment on changes in weight, blood pressure, inflammatory and haemostatic markers of cardiovascular disease, and mood.</outcome>
      <timepoint> The study will provide efficacy and tolerability data on the study treatment given for a total of 12 weeks. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lipid profile (TC, LDL-C, HDL-C, TG [primary]; LDL-particle size, Apo B), inflammatory markers (hsC-RP, LFT, FBC, ESR, ferritin), haemostatic clotting (fibrinogen), blood pressure, body mass index (BMI), body weight, waist to hip ratio, mood (GHQ 28-item general health questionnaire) and health-related quality of life (SF-36 item short form questionnaire).</outcome>
      <timepoint>Will be collected at baseline and 12 weeks.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. CT confirmed first-ever or recurrent ischaemic stroke  2. Clinically stable with atheromatous disease history greater than 3 months.</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Known intolerance or hypersensitivity to fish and /or fish oils.  2. Current use of fish oils (dietary supplements) 3. Known to be pregnant or breast feeding 4. Active disease causing malabsorption.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed numbered envelopes.</concealment>
    <sequence>Identical opaque gelatin capsules will be assigned and presented in identical foil blister packs in sealed numbered envelopes. Sealed master envelopes have been prepared by the blister pack manufacturer and sent directly to the Data and Safety Monitoring Board and to the Chief Executive Officer of FPA Health. The treatment codes will only be broken following completion of the analysis of the primary end point.  Therefore, allocation concealment will be maintained until the end of the study.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/06/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>220</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Health Research Council (New Zealand)</primarysponsorname>
    <primarysponsoraddress>Level 3, 110 Stanley Street, Auckland, 1010, New Zealand</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council</fundingname>
      <fundingaddress>Level 3, 110 Stanley Street, Auckland, 1010, New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>CTRU, The University of Auckland</sponsorname>
      <sponsoraddress>Level 4, School of Population Health, Tamaki Campus, University of Auckland, Glen Innes, Auckland 1072</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Colin Howe</name>
      <address>Clinical Trials Reseach Unit
University of Auckland
Private Bag 92019
Glen Innes Auckland 1</address>
      <phone>+64 9 3737999</phone>
      <fax>+64 9 3731710</fax>
      <email>c.howe@ctru.auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Colin Howe</name>
      <address>Clinical Trials Reseach Unit
University of Auckland
Private Bag 92019
Glen Innes Auckland 1</address>
      <phone>+64 9 3737999</phone>
      <fax>+64 9 3731710</fax>
      <email>c.howe@ctru.auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email>regtrials@ctru.auckland.ac.nz</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>